UTIs are Common and Not Addressed Enough

UTIs are a common problem! UTIs annually affect 30 million people and are responsible for the single-greatest use of antibiotics outside of hospital settings in the U.S.

Women are disproportionately affected, with 60% of women in the U.S. acquiring a UTI in their lifetime, compared with 14% of men. However, these statistics are underestimated according to researchers, as about 50% of UTIs do not get medical attention and are not noted.

The conventional medical standard of care for treating UTIs are a full dose of antibiotics. There are multiple antibiotics that are effective in the short term to treat UTIs. However, these antibiotics create a higher probability of recurrent UTIs. Fifty-three percent of females with their first UTI experience a second UTI within 6 to 12 months. This hardly seems like an effective treatment for preventing recurrent UTIs.

Given the exponential increase in antibiotic resistance worldwide over the past few decades, antibiotics as the conventional medical standard of care for UTIs have become less attractive and responsible for the high rate of antibiotic-resistant UTIs and a variety of urogenital conditions and cancers, including bladder cancer, the sixth most common cancer.

Most of the world’s biggest pharmaceutical companies have determined that they are unable to profit significantly from antibiotics and, as such, have stopped investing in alternative ways to treat UTIs.

This has led to an ever increasing and prevalent health problem, namely recurrent UTIs, that disproportionally affects women and remains inappropriately treated and underinvested in. Here is the opportunity that Curogenix will address and show the world its power.